— Know what they know.
Not Investment Advice

CMPS NASDAQ

COMPASS Pathways plc
1W: -10.9% 1M: -26.8% 3M: +22.1% YTD: +65.7% 1Y: +150.6% 3Y: +21.1% 5Y: -70.7%
$10.85
-0.42 (-3.73%)
 
Weekly Expected Move ±10.0%
$9 $10 $11 $12 $14
NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 35 · $1.5B mcap · 101M float · 4.50% daily turnover · Short 38% of daily vol
Smart Money Score
Moderate 50
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$1.5B
52W Range3.92-15.4
Volume2,621,738
Avg Volume4,567,676
Beta2.49
Dividend
Analyst Ratings
14 Buy 0 Hold 0 Sell
Consensus Buy
Company Info
CEOKabir Kumar Nath
Employees156
SectorHealthcare
IndustryBiotechnology
IPO Date2020-09-18
33 Broadwick Street
London, CH W1F 0DQ
GB
44 64 6905 3974
About COMPASS Pathways plc

COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.

Recent Insider Trades

NameTypeSharesPriceDate
Riley Wayne Joseph A-Award 21,110 $11.85 2026-05-27
McQuade Robert A-Award 21,110 $11.85 2026-05-27
Norton David Y A-Award 21,110 $11.85 2026-05-27
Tregoning Kathleen A-Award 41,119 $11.85 2026-05-27
Tregoning Kathleen 0 2026-05-27

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms